Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Earnings for Erasca, Inc. (ERAS)
Earnings in 2023 (TTM): $-125,042,000
According to Erasca, Inc.'s latest financial reports the company's current earnings (TTM) are $-125,042,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Erasca, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-125,042,000 | $-125,042,000 |
| 2022 | $-242,805,000 | $-238,160,000 |
| 2021 | $-122,764,000 | $-150,090,000 |
| 2020 | $-101,660,000 | $-173,069,000 |
| 2019 | $-12,040,000 | $-10,737,000 |